Log in to save to my catalogue

Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomet...

Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomet...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_98d8349f6793447b88974dcf1c4a8542

Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure

About this item

Full title

Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure

Publisher

England: BioMed Central Ltd

Journal title

Journal of hematology and oncology, 2022-01, Vol.15 (1), p.12-10, Article 12

Language

English

Formats

Publication information

Publisher

England: BioMed Central Ltd

More information

Scope and Contents

Contents

Treated secondary acute myeloid leukemia (ts-AML)-i.e., AML arising from a previously treated antecedent hematologic disorder-is associated with very poor outcomes. The optimal frontline treatment regimen for these patients is uncertain.
We retrospectively analyzed 562 patients who developed AML from preceding myelodysplastic syndrome or chronic...

Alternative Titles

Full title

Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_98d8349f6793447b88974dcf1c4a8542

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_98d8349f6793447b88974dcf1c4a8542

Other Identifiers

ISSN

1756-8722

E-ISSN

1756-8722

DOI

10.1186/s13045-022-01229-z

How to access this item